Drug Profile
Research programme: small molecule anti-cancer therapeutics - Peloton Therapeutics/University of Texas Southwestern Medical Center
Alternative Names: PT 2399Latest Information Update: 07 Aug 2019
Price :
$50
*
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer Peloton Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin protein ligase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jul 2019 Peloton Therapeutics has been acquired by Merck & Co
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 15 Jun 2017 Peloton Therapeutics and University of Texas Southwestern Medical Center agree to co-develop small molecule anti-cancer therapeutics for Cancer